As expected, the master regulator IKZF1 overexpression led to enhanced immune infiltrate recruitment and tumor sensitivity to PD-1 and CTLA-4 inhibitors in cancers that typically lack IKZF1 expression [100]. The gene discussed is CTLA4; the disease is cancer.